Single-cell eQTL Mendelian randomization reveals the monocyte-associated PRKCB–CTSL axis as a candidate regulatory pathway and potential therapeutic target in rheumatoid arthritis
4 affiliations
- 1Department of Pediatric Surgery, Beijing Anzhen Nanchong Hospital of Capital Medical University & Nanchong Central Hospital, Second Clinical Medical College of North Sichuan Medical College, No. 97 Renmin South Road, Shunqing, Nanchong, 637000 Sichuan China
- 2Department of Clinical Medicine, Ningxia Medical University, Hui Autonomous Region, Yinchuan, Ningxia 750004 People’s Republic of China
- 3School of Basic Medicine and Forensic Medicine, North Sichuan Medical College, No.234 Fujiang Road, Shunqing District, Nanchong, Sichuan, 637000 China
- 4North Sichuan Medical College, No. 234 Fu Jiang Road, Shunqing, Nanchong, 637000 Sichuan People’s Republic of China
Abstract
Objectives: Rheumatoid arthritis (RA) involves persistent immune dysregulation, but cell-specific genetically regulated pathways remain unclear. We integrated cell-specific genetic and multi-omics evidence to prioritize candidate regulatory pathways.
Methods: cis-eQTLs from 17 immune-cell populations were integrated with RA GWAS data by two-sample Mendelian randomization. Transcriptomics, WGCNA, and machine-learning feature selection identified convergent candidates. Single-cell and virtual perturbation analyses assessed cellular localization and downstream changes. Molecular docking and dynamics computationally prioritized compounds, and knockdown/rescue experiments evaluated the PRKCB–CTSL relationship.
Results: Eleven candidates had convergent genetic and transcriptomic support. PRKCB was retained by LASSO, SVM, and random forest and preferentially expressed in monocytes. Virtual perturbation implicated CTSL and antigen-processing/presentation pathways. PRKCB knockdown reduced CTSL expression and NF-κB phosphorylation, whereas CTSL restoration partially rescued NF-κB phosphorylation. Separately, structure-based analyses computationally prioritized ursodiol for the most favorable predicted PRKCB interaction among evaluated compounds.
Conclusions: Genetic, transcriptomic, single-cell, computational, and in vitro evidence supports monocyte-associated PRKCB–CTSL as a candidate regulatory pathway in RA. Further mechanistic and in vivo studies are required to establish its causal and pharmacological relevance. Key Points
• Multi-omics analysis identified 11 key RA-associated targets.
• RA was classified into two molecular subtypes with distinct immune features.
• PRKCB was identified as the core target enriched in monocytes.
• The PRKCB–CTSL axis may drive RA inflammation, and ursodiol showed therapeutic potential.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s10067-026-08482-4.
Related
- Bidirectional Mendelian randomization analysis reveals the causal relationship between rheumatoid arthritis and acute sinusitis
- Identification of genetically supported candidate therapeutic targets for angina pectoris using mendelian randomization
- Rheumatoid Arthritis and Thrombocytopenia: Causal Evidence and Prognostic Implications From Observational and Mendelian Randomization Analyzes.
- Identification of Genes Associated with Gut Microbiota Metabolites in Type 2 Diabetes Mellitus Complicated by Acute Cerebral Infarction Based on Bioinformatics and Mendelian Randomization
- Complement Component C4B Prioritization Through Drug‒Target Mendelian Randomization and Proteomic Analysis Reveals a Novel Therapeutic Target for Calcific Aortic Valve Stenosis
BibTeX
@article{wang2026singlecell,
title = {{Single-cell eQTL Mendelian randomization reveals the monocyte-associated PRKCB–CTSL axis as a candidate regulatory pathway and potential therapeutic target in rheumatoid arthritis}},
author = {Pengli Wang and Guohang Shen and Wenhua Liao and Ruoyan Wang and Li Zhang and Mingjia Zhao and Dong Zhang and Nanxiang Huang and Yupei Dai},
journal = {Clinical Rheumatology},
year = {2026},
month = oct,
doi = {10.1007/s10067-026-08482-4},
url = {https://doi.org/10.1007/s10067-026-08482-4},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Single-cell eQTL Mendelian randomization reveals the monocyte-associated PRKCB–CTSL axis as a candidate regulatory pathway and potential therapeutic target in rheumatoid arthritis
AU - Pengli Wang
AU - Guohang Shen
AU - Wenhua Liao
AU - Ruoyan Wang
AU - Li Zhang
AU - Mingjia Zhao
AU - Dong Zhang
AU - Nanxiang Huang
AU - Yupei Dai
PY - 2026
DA - 2026/10/19
JO - Clinical Rheumatology
DO - 10.1007/s10067-026-08482-4
UR - https://doi.org/10.1007/s10067-026-08482-4
AB - Objectives: Rheumatoid arthritis (RA) involves persistent immune dysregulation, but cell-specific genetically regulated pathways remain unclear. We integrated cell-specific genetic and multi-omics evidence to prioritize candidate regulatory pathways. Methods: cis-eQTLs from 17 immune-cell populations were integrated with RA GWAS data by two-sample Mendelian randomization. Transcriptomics, WGCNA, and machine-learning feature selection identified convergent candidates. Single-cell and virtual perturbation analyses assessed cellular localization and downstream changes. Molecular docking and dynamics computationally prioritized compounds, and knockdown/rescue experiments evaluated the PRKCB–CTSL relationship. Results: Eleven candidates had convergent genetic and transcriptomic support. PRKCB was retained by LASSO, SVM, and random forest and preferentially expressed in monocytes. Virtual perturbation implicated CTSL and antigen-processing/presentation pathways. PRKCB knockdown reduced CTSL expression and NF-κB phosphorylation, whereas CTSL restoration partially rescued NF-κB phosphorylation. Separately, structure-based analyses computationally prioritized ursodiol for the most favorable predicted PRKCB interaction among evaluated compounds. Conclusions: Genetic, transcriptomic, single-cell, computational, and in vitro evidence supports monocyte-associated PRKCB–CTSL as a candidate regulatory pathway in RA. Further mechanistic and in vivo studies are required to establish its causal and pharmacological relevance. Key Points • Multi-omics analysis identified 11 key RA-associated targets. • RA was classified into two molecular subtypes with distinct immune features. • PRKCB was identified as the core target enriched in monocytes. • The PRKCB–CTSL axis may drive RA inflammation, and ursodiol showed therapeutic potential. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s10067-026-08482-4.
SN - 0770-3198
SN - 1434-9949
ER -